Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (536)	6/14/2001 12:51:54 PM
From: juneau_boy	Read Replies (1) \| Respond to of 3557

Regeneron Elects Dr. George D. Yancopoulos to Board of Directors TARRYTOWN, N.Y., Jun 14, 2001 (BUSINESS WIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN chart, msgs) announced that George D. Yancopoulos, M.D., Ph.D., has been elected to its Board of Directors. Dr. Yancopoulos is currently President, Regeneron Research Laboratories, and Executive Vice President and Chief Scientific Officer of the Company. Dr. Yancopoulos joined Regeneron in 1989. He received his Ph.D. in Biochemistry and Molecular Biophysics and his M.D. from Columbia University. P. Roy Vagelos, M.D., Chairman of the Board of Regeneron, commented, "George Yancopoulos is one of the most outstanding of today's scientists conducting research on the frontiers of medicine. Through his leadership, Regeneron continues to make discoveries that lead to potential major new drugs. We look forward to George's further contributions as a member of our Board of Directors." Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. Regeneron's platform technologies include Targeted Genomics(TM), Functionomics(TM), and Designer Protein Therapeutics(TM). Regeneron has drugs in clinical trials for the potential treatment of obesity and rheumatoid arthritis, and has preclinical development programs in cancer, asthma, allergies, and other diseases and disorders. This news release discusses historical information and includes forward-looking statements about Regeneron and about its products, programs, finances, and business, all of which involve a number of risks and uncertainties, such as risks associated with preclinical and clinical development of drugs and biologics, determinations by regulatory and administrative governmental authorities, competitive factors, technological developments, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any collaboration agreement to be canceled or to terminate without any product success, and other material risks. A more complete description of these risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its current Form 10-Q and its Form 10-K for the year ending December 31, 2000. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise uless required by law. Contact: Promoting from within...long time insider...good signs IMHO